An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M. Jotte, Robert Ilaria, Daniel D. Von Hoff et al.|Investigational New Drugs|2014Cited by 10
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.Manuel Hidalgo, Daniel D. Von Hoff, Joon Oh Park et al.|Journal of Clinical Oncology|2018Cited by 6
Novel organic arsenic molecule darinaparsin: Development of IV and oral formsIzidore S. Lossos, Wilson H. Miller, Michael Craig et al.|Journal of Clinical Oncology|2009Cited by 5
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.Manuel Hidalgo, Daniel D. Von Hoff, Ron Epelbaum et al.|Journal of Clinical Oncology|2018Cited by 0